Allergan Third-Quarter Profit Tops Estimates as Sales ClimbBy
Revenue from top drugs Botox, Namenda is short of estimates
Company doesn't expand on previous comments on Pfizer deal
Allergan Plc, Pfizer Inc.’s target in a deal that could be the largest health-care acquisition of all time, reported third-quarter earnings that topped analysts’ estimates as the company’s recent takeovers added to revenue.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.